GLOFIL-125
LOE Approachingsodium iothalamate i-125 injection
NDAINJECTIONINJECTABLE
Approved
Feb 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GLOFIL-125 (sodium iothalamate i-125 injection) is clinical pharmacology the renal clearance of sodium iothalamate in man closely approximates that of inulin. First approved in 1974.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLOFIL-125 is a radioactive diagnostic agent containing sodium iothalamate labeled with iodine-125, used to measure glomerular filtration rate (GFR) and assess renal function. The compound is cleared exclusively by glomerular filtration without tubular reabsorption or secretion, making it a gold-standard agent for precise renal clearance measurement. It is administered via injection and has a short effective half-life of approximately 0.07 days.
LOE Approaching
This legacy diagnostic product faces declining relevance with limited commercial team expansion; roles are typically focused on maintaining existing hospital and lab partnerships rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GLOFIL-125 offers limited career growth potential given the product's mature, diagnostic-only status and approaching loss of exclusivity; roles are primarily account management and relationship maintenance rather than strategic launches. This position is best suited for professionals seeking stable, specialized diagnostic expertise in nuclear medicine or renal diagnostics rather than high-growth commercial opportunity.
Diagnostic Product Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.